PD | PSP | CBD | p | |
---|---|---|---|---|
Age (years) | 69.0 | 70.9 | 62.0 | 0.005 |
Gender (men/women) | 58/30 | 13/17 | 10/9 | 0.2 |
Handedness (right/left/ambidextrous) | 74/13/1 | 29/1 | 16/3 | 0.5 |
Years of education | 11.9 | 12.0 | 13.0 | 0.3 |
UPDRS III (on therapy) | - | 29.7 | 29.0 | 0.8 |
MDS-UPDRS III (on therapy) | 30.5 | – | – | – |
Duration of symptoms at baseline (years) | 1.8 | 3.2 | 3.1 | <0.0001 |
Percentage on dopaminergic therapy | 45.3 | 18.1 | 30 | 0.05 |
Mean levodopa dose of those on medication (mg) | 273.6 | 220.0 | 266.7 | 0.7 |
p Values based on F tests in one-way analysis of variance, or χ2, as appropriate.
CBD, corticobasal degeneration; PD, Parkinson's disease; PSP, progressive supranuclear palsy.